ELYM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 16:00):

Stats
Today's Volume	385 555
Average Volume	831 981
Market Cap	232.60M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.45
ATR14	$0.0500 (0.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Morisset Valerie	Buy	17 847	Common Stock
2024-04-05	Morisset Valerie	Sell	17 847	Stock Option (Right to Buy)
2024-03-18	Pimblett Emily	Buy	40 000	Restricted Stock Units
2023-09-20	Morisset Valerie	Buy	15 297	Common Stock
2023-09-20	Morisset Valerie	Buy	5 431	Common Stock

INSIDER POWER
39.76
Last 75 transactions
Buy: 17 601 902 \| Sell: 12 020 423

Volume Correlation

Long: -0.06 (neutral)

Short: -0.73 (moderate negative)

Signal:(41.641) Neutral

Eliem Therapeutics, Inc. Correlation

10 Most Positive Correlations
BNIXU	0.883

10 Most Negative Correlations
GOODM	-0.847
RMRM	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eliem Therapeutics, Inc. Correlation - Currency/Commodity

0.07
( neutral )

-0.23
( neutral )

0.00
( neutral )

0.06
( neutral )

0.46
( neutral )

-0.03
( neutral )

Eliem Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.300

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.300

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.720

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.05

Financial Reports:

No articles found.

Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.